Abstract

Objective To provide an overview of rheumatoid arthritis (RA) and the medications presently being used to treat the disease. Data Sources References have been selected from published articles, monographs, manufacturers’ product information, textbooks on therapeutics of rheumatic diseases, and specific computerized databases such as DRUGDEX. Study Selection Studies that establish the pharmacokinetics of the various drugs have been included, as have comparative studies of the various agents. Studies that gave specifics concerning the use of the various agents in the elderly were given priority in selection. Monographs from both United States Pharmacopeia Dispensing Information and American Hospital Formulary Service Drug Information ‘92 were used to ensure consistency in dosing and pharmacokinetic data. Data Synthesis A variety of medications are used to treat RA, and are classified according to their ability to alleviate the inflammatory process and symptomatology of the disease, or to actually slow down or halt the progression of the disease process itself. The long-established pyramidal approach to therapy is presently being challenged so as to employ the slow-acting or disease-modifying agents earlier in the process. Conclusions A wide variety of medications are presently available for treating RA. As the pathogenesis of the disease becomes better defined, it is hoped that less-toxic and more-specific and -effective therapies will become available. Medications remain the cornerstone of therapy; however, patient education, rest, and exercise are equally important.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.